Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study by Peralta Fernández, Francisco Galo et al.
Peralta et al. BMC Infectious Diseases 2012, 12:245
http://www.biomedcentral.com/1471-2334/12/245RESEARCH ARTICLE Open AccessImpact of empirical treatment in
extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella spp. bacteremia.
A multicentric cohort study
Galo Peralta1*, María Lamelo2, Patricia Álvarez-García2, María Velasco3, Alberto Delgado3, Juan Pablo Horcajada4,
María Montero4, María Pía Roiz5, Maria Carmen Fariñas5, Juan Alonso5, Luis Martínez Martínez5,
Alfonso Gutiérrez-Macías6, Jose Angel Alava6, Azucena Rodríguez7, Ana Fleites7, Vicente Navarro8, Elia Sirvent8
Jose Antonio Capdevila9, and on behalf of the SEMI- BLEE STUDY GROUP (members of SEMI BLEE group were
listed in the acknowledgments section)Abstract
Background: The objective of this study is to analyze the factors that are associated with the adequacy of
empirical antibiotic therapy and its impact in mortality in a large cohort of patients with extended-spectrum
β-lactamase (ESBL) - producing Escherichia coli and Klebsiella spp. bacteremia.
Methods: Cases of ESBL producing Enterobacteriaceae (ESBL-E) bacteremia collected from 2003 through 2008 in
19 hospitals in Spain. Statistical analysis was performed using multivariate logistic regression.
Results: We analyzed 387 cases ESBL-E bloodstream infections. The main sources of bacteremia were urinary tract
(55.3%), biliary tract (12.7%), intra-abdominal (8.8%) and unknown origin (9.6%). Among all the 387 episodes, E. coli
was isolated from blood cultures in 343 and in 45.71% the ESBL-E was multidrug resistant. Empirical antibiotic
treatment was adequate in 48.8% of the cases and the in hospital mortality was 20.9%. In a multivariate analysis
adequacy was a risk factor for death [adjusted OR (95% CI): 0.39 (0.31-0.97); P = 0.04], but not in patients without
severe sepsis or shock. The class of antibiotic used empirically was not associated with prognosis in adequately
treated patients.
Conclusion: ESBL-E bacteremia has a relatively high mortality that is partly related with a low adequacy of
empirical antibiotic treatment. In selected subgroups the relevance of the adequacy of empirical therapy is limited.
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Escherichia coli and Klebsiella spp. are the most import-
ant causal agents of Gram negative bacteremia both in
hospital and community acquired bloodstream infections
[1,2]. These Enterobacteriaceae are increasingly worldwide
resistant to antimicrobials [3,4]. One of the main causes for
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reproduction in any medium, provided the orspectrum beta-lactamases (ESBL), a family of plasmid-
encoded enzymes that hydrolyse and cause resistance to
most of the beta-lactam antibiotics, including penicillins,
monobactams and most cephalosporins. Because ESBL-
producing Enterobacteriaceae (ESBL-E) are also frequently
resistant to other non-related beta-lactam antibiotics as
quinolones, trimethoprim-sulfamethoxazole, and amino-
glycosides, the recommended empirical antibiotic therapy
when these infections are suspected are wide spectrum
antimicrobials, essentially carbapenems [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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iaceae has resulted in increased use of carbapenems,
which exhibit potent activity against many ESBL-
harboring microorganisms. This in turn has led to an
emergence and increase in resistance to carbapenems
among Enterobacteriaceae [6].
In this epidemic hallmark of ESBL-E infections infor-
mation about its optimal antimicrobial therapy is needed.
In this sense, ESBL-E are often susceptible in vitro to
some antimicrobials as beta-lactam/beta-lactam inhibi-
tors, and some data support their potential role in the
treatment of these infections although information about
this subject in clinical practice is quite limited.
The aim of this study is to analyze the impact of
adequacy of empirical antibiotic therapy in mortality in
a large cohort of patients with ESBL-E bacteremia.
Methods
Study population
We studied cases of ESBL-E bacteremia diagnosed from
January 2004 through December 2008 in 19 Spanish
Hospitals, included in the Infectious Diseases Research
Group of the Spanish Society of Internal Medicine.
Cases were identified using the microbiology laboratory
databases and reviewed by internal medicine/infectious
diseases physicians.
Data collection and definitions
Patients were identified retrospectively and reviewed
using a standardized data collection sheet. Only the first
episode of mono-microbial bacteremia of each patient
was selected for the study. All charts were reviewed. A
multi-institutional database was developed including the
following variables: age, sex, origin of bacteremia, dates
of hospital admission and discharge, comorbidities, anti-
microbial therapy, surgical procedures, hospitalization in
an intensive care unit, and in-hospital mortality.
Bacteremia was considered to have been nosocomially
acquired if appearing 48 hours after admission and no evi-
dence of infection was present on admission. Episodes
were considered health care–associated according to the
criteria of Friedman et al [7]. The source of bacteremia
was determined by clinical assessment and appropriate
cultures (urine, sputum. . .) when available. Renal failure
was defined by a creatinine value >2.0 mg/dL. Neutro-
penia was defined as an absolute neutrophil count of <500
cells/mm3 at the onset of the bacteremia. Immunosup-
pression was defined as the presence of neutropenia or
HIV infection (with CD4 count <350 cells/mm3), or im-
munosuppressive therapy. Co-morbidities were assessed
by using the Charlson co-morbidity score [8]. Sepsis, se-
vere sepsis and septic shock were defined according to the
American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference [9]. Empiricalantimicrobial therapy was defined as adequate in terms of
in vitro susceptibility of an organism isolated, and if anti-
biotic treatment was started within 24 hours after drawing
blood cultures. The correction for definitive therapy was
defined as that implemented after blood cultures results
was obtained in patients with inadequate empirical ther-
apy, and also was considered adequate or inadequate in
terms of in vitro susceptibility of an organism isolated.
Oxyimino-beta-lactams (cefuroxime, cefotaxime, ceftriax-
one, ceftazidime and aztreonam) were considered to be in-
appropriate, regardless of the MIC, for the treatment of
infections caused by ESBL-producing Enterobacteriaceae.
Therapy with urinary antiseptics such as norfloxacin, fos-
fomycin, pipemidic acid or nalidixic acid was considered
inadequate [10]. Organisms reported as intermediate in
susceptibility to a particular antibiotic were classified as
non-susceptible for this report. ESBL-E showing resistance
to at least 1 representative of 2 other families of antibiotics
(fluoroquinolones, beta-lactam/beta-lactam combinations,
or aminoglycosides) were considered multidrug resistant
(MDR). The dosage of the antibiotic was not taken into
account when assessing adequacy. All study definitions
were established before data analysis. The study was
approved by the Regional Institutional Review Board of
Cantabria.Microbiological studies
ESBL-E isolation and identification were performed fol-
lowing standard methods at each centre. ESBL produc-
tion was screened at the same time by the double disc
synergy method as a complementary test for automated
systems, at each centre. Minimal inhibitory concentra-
tions were interpreted according to Clinical and Labora-
tory Standards Institute guidelines [11].Statistical analysis
Based on the results of the literature a sample size calcula-
tion was performed with the openepi program (www.
openepi.com). A mortality of 20% was considered in the
adequate empirical treatment group and of 35% in the in-
adequate treatment group. For a power of 80% and a level
of significance of 0.05, an overall sample of 270 patients
was required (50% with adequate empirical treatment).
Categorical data were compared by the x2 or Fisher’s
exact tests. Quantitative data were compared by Stu-
dent’s t-test or the Mann–Whitney U-test, as appropri-
ate. All reported p values are two-sided and have not
been adjusted for multiple testing. Variables with a p
crude value <0.1 in the univariate analysis were candi-
dates for multivariate analysis and possible interactions
were evaluated. The analysis was performed with the
stepwise logistic–regression model of the SPSS software
package. All subgroup analysis was a priori defined.




Age (mean, range) 70.3, 0-96 y
Age> 65 y 280 (72.4)
Place of acquisition
Community acquired 110 (28.4)

















Chronic renal failure 68 (17.6)
Cardiac failure 56 (14.5)
Liver cirrhosis 44 (11.4)
Metastatic tumor 33 (8.5)
Charlson ≥3 209 (54)
Date are no. (%) of patients; COPD: chronic obstructive pulmonary disease.
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Clinical features, adequacy of empirical therapy and
temporal trends
The study included 399 patients detected in the participat-
ing centres. Excluded from the study were 12 (3%)
patients due to insufficient data for the analysis. Among
the remaining 387 patients, in hospital mortality was
20.9%. E. coli was isolated from blood cultures in 343
(88.6%) cases and K. pneumoniae in 44 cases (11.4%). The
mean ± standard deviation patient age was 70.3± 16 years.
Three patients were neonates (one with bacteremia caused
by E. coli and two by K. pneumoniae). Seventy-two
patients (18.6%) had severe sepsis and fifty-three (13.7%)
had septic shock as a manifestation of the ESBL-E
bacteremia. Median Charlson index was 3 (range 0-12).
Table 1 shows the characteristics of the patients. Percent-
age of non-susceptibility of ESBL-E to antimicrobial was:
quinolones: 82.9%, amoxicillin-clavulanate: 40.3%, genta-
micin: 27.1%, piperacillin-tazobactam: 16.8% and carbape-
nem: 0%. In 45.7% of the cases the ESBL-E was multidrug
resistant. In 189 (48.8%) episodes of bacteremia, the em-
pirical antibiotic treatment was inadequate according to
the microbiological results. In 44 (11.4%) episodes the de-
finitive antibiotic treatment was inadequate. Of these
patients with definitive inadequate therapy 24 (54.5%)
patients died in the first three days after blood cultures
extraction.
Of the 387 episodes of bacteremia 84 (21.7%) were
detected in the period 2004-2005, and 303 (78.3%) in the
period 2006-2008. When we compared the characteristics
of the patients between these two periods we detected sig-
nificant differences proportion in the frequency of empir-
ical antibiotic treatment with piperacillin-tazobactam
(7.3% vs. 14.9%, p = 0.03). Respect to E-ESBL resistance
pattern, a trend to decrease in susceptibility from the first
to the second period to amoxicillin-clavulanate (66.7% vs.
57.8%, p = 0.08) and decrease to ciprofloxacin (25% vs.
14.9%, p = 0.02) was detected and an increase in the pro-
portion of multiresistant infections (35.7% vs. 48.5%,
p = 0.02). A trend to decrease in the proportion of patients
with community acquired infections was also detected
(35.7% vs 26.4%, p = 0.06).Risk factors for mortality
The results of the univariate analysis of the risk factors
associated with in hospital mortality are reflected in Table 2.
Variables associated with mortality in the multivariate ana-
lysis were: hospital acquisition [adjusted OR (95% CI): 3.41
(1.89-6.18); P <0.001], presence of metastatic disease
[adjusted OR (95% CI): 4.2 (1.78-9.95); P= 0.001], adequacy
of empirical antibiotic therapy [adjusted OR (95% CI): 0.39
(0.31-0.97); P=0.04], presence of severe sepsis or shock
[adjusted OR (95% CI): 11.66 (6.28-21.65) P<0.001].A multivariate analysis selecting patients without severe
sepsis or shock showed that adequate empirical therapy
was not associated with mortality in this group, but it was
associated with mortality in patients with severe sepsis or
shock (adjusted OR, 0.42; 95% CI, 0.19–0.92; P = 0.03).Antibiotic therapy and prognostic factors in adequately
treated patients
The most frequent empirical antibiotic treatments in
the entire cohort were carbapenem (18.1%), amoxicillin/
clavulanate (17.6%), ciprofloxacin or levofloxacin (16%),
ceftriaxone or cefotaxime (12.9%) and piperacillin/
tazobactam (12.9%).
A stratified analysis of mortality considering adequacy
with different empirical antibiotic treatments is reflected
in Table 3. For the group of patients who received ad-
equate empirical treatment with beta-lactam/beta-lactam
inhibitor combinations or with carbapenem mortality
Table 2 Factors associated with mortality in patients with E. coli or Klebsiella spp. bacteremia
Death Survival p RR (95 % CI)
(n = 81) (n = 306)
Demographics
Men 57 (70.4) 207 (61.8) 0.1 1.36 (0.89-2.09)
Age> 65 y 61 (75.3) 219 (71.6) 0.3 1.17 (0.74-1.83)
Place of acquisition
Community acquired 13 (16) 97 (31.7) 0.003 0.41 (0.22-0.78)
Health care associated 25 (30.9) 112 (36.6) 0.2 0.82 (0.53-1.24)
Nosocomial 43 (53.1) 97 (31.7) <0.001 2 (1.36-2.93)
Origin of infection
Urinary 38 (46.9) 177 (57.8) 0.05 0.71 (0.48-1.04)
Biliary 8 (9.9) 41 (13.4) 0.26 0.76 (0.39-1.47)
Unknown 9 (11.1) 28 (9.2) 0.36 1.18 (0.64-2.16)
Intra-abdominal 11 (13.6) 23 (7.5) 0.07 1.63 (0.96-2.77)
Pneumonia 8 (9.9) 20 (6.5) 0.21 1.41 (0.75-2.61)
Catheter 3 (3.7) 13 (4.2) 0.56 0.89 (0.32-2.52)
Comorbidity
Diabetes 21 (25.9) 91 (29.7) 0.3 0.86 (0.55-1.34)
Ictus 15 (18.5) 55 (18) 0.51 1.03 (0.63-1.69)
Dementia 16 (19.8) 50 (16.3) 0.28 1.2 (0.74-1.93)
COPD 15 (18.5) 50 (16.3) 0.38 1.12 (0.69-1.84)
Chronic renal failure 20 (24.7) 48 (15.7) 0.05 1.54 (1-2.37)
Cardiac failure 15 (18.5) 41 (13.4) 0.16 1.34 (0.83-2.18)
Liver cirrhosis 16 (19.8) 28 (9.2) 0.009 1.92 (1.23-3)
Cancer 33 (40.7) 78 (25.5) 0.006 1.71 (1.17-2.51)
Metastatic tumor 13 (16) 20 (6.5) 0.009 2.05 (1.28-3.3)
Immunosuppression 16 (19.8) 49 (16) 0.25 1.22 (0.76-1.97)
Charlson ≥3 60 (74.1) 149 (48.7) <0.001 2.43 (1.54-3.84)
Microbiology
E. coli 65 (80.2) 278 (90.8) 0.009 0.52 (0.33-0.82)
Multidrug resistant 45 (55.6) 132 (43.1) 0.03 1.48 (1-2.19)
Presentation
Sepsis severe or shock 57 (70.4) 68 (22.5) <0.001 4.9 (3.2-7.51)
Adequate empirical therapy 34 (42) 164 (53.6) 0.04 0.69 (0.47-1.02)
Adequate change for definitive therapy 29 (32.1) 109 (35.6) 0.33 0.88 (0.58-1.34)
Date are no. (%) of patients.
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(p = 0.05).
A multivariate analysis of risk factors for death of
the patients treated with adequate empirical antibiotics
was performed, including the next variables: urinary
origin, nosocomial acquisition, presence of neoplasm,
presence of metastatic disease, Charlson index score
≥3, bacteremia caused by E. coli, MDR ESBL-E, and
presence of severe sepsis or shock. In this model the
risk factors associated with death were: presence of
neoplasm [adjusted OR (95% CI): 4.32 (1.81-10.31);
P = 0.001], presence of sepsis severe or shock [adjustedOR (95% CI): 8.62 (3.48-21.34); P < 0.001], and nosoco-
mial acquisition [adjusted OR (95% CI): 2.93 (1.21-7.11);
P = 0.02].
Discussion
ESBL-E are rising worldwide as a cause of bloodstream
community acquired, health related or nosocomial
acquired infections [2-6,10,12-17]. In this context informa-
tion about optimal therapeutic options for these infections
in daily practice and their repercussion on outcome is
needed. Several studies about ESBL-E bloodstream infec-
tions have analyzed the adequacy of empirical antibiotic
Table 3 Mortality among patients with E. coli or Klebsiella spp. bacteremia treated empirically with different
antimicrobials depending on the adequacy
Adequate Inadequate p RR (95% CI)
Beta-lactam/Beta-lactam inhibitor combinations (n = 117) 11 (13.1) 13 (39.4) 0.002 0.58 (0.37-0.91)
Amoxicillin/clavulanate (n = 67) 3 (7.5) 10 (37) 0.004 0.34 (0.12-0.92)
Piperacillin/tazobactam (n = 50) 8 (18.2) 3 (50) 0.11 0.79 (0.54-1.14)
Quinolones (n = 62) 0) 10 (20.4) - -
Carbapenem (n = 70) 18 (25.7) - - -
Cefotaxime or ceftriaxone (n = 50) - 7 (14) - -
Aminoglycoside monotherapy* (n = 22) 3 (23.1) 2 (22.2) 0.68 1.02 (0.45-2.31)
None antimicrobial (n = 25) - 7 (28) - -
Overall (n = 387) 34 (17.2) 47 (24.9) 0.04 0.78 (0.59-1.03)
Date are no. (%) of patients. *Patients with only aminoglycoside as empirical antibiotic ESBL-E susceptible.
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equacy and outcome, with dissimilar results [6,12-15]. Dis-
cordance among series is relevant and is probably related,
at least in part, with the limited number of cases in most of
the studies, differences in the selected population, and dif-
ferences in definitions. The present study represents one of
the largest series even communicated of patients with
ESBL-E bacteremia. Our results corroborate the relatively
high mortality of ESBL-E bloodstream infections and
underscore the relevance of adequacy of antibiotic treat-
ment on mortality in ESBL-E bacteremia. Our study also
reveals a role for beta-lactam/beta-lactam inhibitor combi-
nations in the treatment of ESBL-E infections.
A triangle of relationships among resistance, adequacy
and mortality in bloodstream infections has previously
emphasized as one of the potential causes for the higher
mortality of infections caused by MDR agents, including
ESBL-E [5,13]. The general assumption of the causal
connections of this triangle is the basis for the recom-
mendation of wide spectrum antibiotic as empirical ther-
apy in patients at risk of MDR infections. In ESBL-E
infections carbapenems are widely considered as the
drugs of choice on the basis on study cohorts, most of
them retrospective, which suggests that third genera-
tions cephalosporins, irrespectively of in vitro suscepti-
bility, and quinolones, are less effective for the treatment
of these infections than carbapenems [15-17]. In vitro
tests that indicate an inoculum effect for beta-lactam/
beta-lactam inhibitor combinations, cephalosporins, and
to a lesser extent with the quinolones, also support this
practice [18]. As community acquired, health related
and hospital acquired ESBL-E bloodstream infections
are increasing, a raise in the empirical use of carbape-
nems in patients with suspected bloodstream infections
and risk factors for ESBL-E acquisition is expected. In
this hallmark with clinicians forced to use the carbape-
nems as the first choice for empirical treatment of severe
infections, a future rise of the resistances to carbape-
nems has been predicted [19,20].The exact role of beta-lactam/beta-lactam inhibitor
combinations in the treatment of ESBL-E infections is
matter of discussion [5-12]. Comparative clinical trials
are lacking, and some recent reports suggest that beta-
lactam/beta-lactam inhibitor combinations are poten-
tially useful in the treatment of in vitro susceptible
isolates [21,23]. A potential role of beta-lactam/beta-
lactam inhibitor combinations in patients with ESBL-E
bloodstream infections is suggested by our data. In our
study mortality is consistently lower in patients treated
empirically with carbapenems, or beta-lactam/beta-
lactam inhibitor combinations when ESBL-E are suscep-
tible although there are many confounding factors that
impede us concluding consistently a role of beta-lactam/
beta-lactam inhibitor combinations in empirical therapy
for patients with ESBL-E bacteremia.
Another question that merit mention is the possibility
of adjusting of antibiotic therapy using beta-lactam/beta-
lactam inhibitor combinations or even quinolones after
evaluating the susceptibility pattern of the ESBL-E in a
“de-escalating” strategy. Our data suggest that beta-
lactam/beta-lactam inhibitor combinations are poten-
tially useful for treating ESBL-E susceptible to these
antimicrobials, and could be an option for de-escalating.
Previous case series have detected a high variability in
the origin of bacteremia, and while in the older reports
the most frequent focus was respiratory tract [13,17,19]
in some of the more recent studies, as in the present
one, the most frequent origin of ESBL-E bacteremia are
urinary and biliary tract [15,16]. This fact can be related
to the higher incidence of hospital-acquired cases (i.e.
ventilator associated pneumonia) at the beginning of the
2000’, and to the more recent “epidemic” increase of
health-related and community acquired E-ESBL infec-
tions [24]. In relation to empirical antibiotic therapy this
is relevant because an effect of adequacy related with the
origin of infection has been previously detected [25],
and suggested by our data. Its cause is unknown, al-
though the lower mortality of ESBL-E bacteremia of
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detected a threefold increase in the number of cases of
ESBL-E bacteremia between 2004-2005 and 2006-2008.
A similar increase has been detected in previous studies.
Our study had several limitations. The study is retro-
spective and the comparisons between groups might be
biased. The absence of a centralized laboratory to
characterize ESBL-E strains and the absence of MICs are
also limitation. Although the number of cases with
ESBL-E is high in relation with previous studies; some
subgroups have small size what may not have allowed us
to find significant differences, especially regarding in
hospital mortality.
In view of the increasing use of empirical carbapenems
due to the risk of ESBL-E infections, information from
clinical prospective studies about optimal empirical ther-
apy for ESBL-E severe infections is needed. However the
feasibility of these studies is uncertain as they imply the
recruitment of a large number of patients with suspected
ESBL-E infections to allow the collection of enough
cases of microbiology proved infections for analysis.
Meanwhile equilibrium among efforts to optimize initial
therapy and efforts to promote judicious use of anti-
microbial should be outweighed, and the role beta-
lactam/beta-lactam inhibitor combinations in ESBL-E
infections should be considered in specific hallmarks,
essentially in de-escalating.
Conclusions
Our results corroborate the relatively high mortality of
ESBL-E bloodstream infections and underscore the rele-
vance of adequacy of antibiotic treatment on mortality
in ESBL-E bacteremia. Our study also reveals a role for
beta-lactam/beta-lactam inhibitor combinations in the
treatment of ESBL-E infections.
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